title: Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
abstract: Glucuronidation by uridine diphospho-glucuronosyltransferase enzymes (UGTs) is a major phase II biotransformation pathway and, complementary to phase I metabolism and membrane transport, one of the most important cellular defense mechanisms responsible for the inactivation of therapeutic drugs, other xenobiotics, and endogenous molecules. Interindividual variability in UGT pathways is significant and may have profound pharmacological and toxicological implications. Several genetic and genomic processes underlie this variability and are discussed in relation to drug metabolism and diseases such as cancer.
authors.affiliation: 1] Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada [2] Pharmacogenomics Laboratory, CHU de Québec Research Center, Québec, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Guillemette
authors.affiliation: 1] Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada [2] Faculty of Medicine, Laval University, Québec, Canada.
authors.forename: É
authors.initials: É
authors.lastname: Lévesque
authors.affiliation: 1] Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada [2] Pharmacogenomics Laboratory, CHU de Québec Research Center, Québec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Rouleau
mesh_terms: D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions / Q000201:enzymology / Q000235:genetics; D014644:Genetic Variation; D005838:Genotype; D020719:Glucuronides / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D007527:Isoenzymes; D050217:Metabolic Detoxication, Phase II / Q000235:genetics; D010597:Pharmacogenetics; D010599:Pharmacokinetics; D010641:Phenotype; D057285:Precision Medicine; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D020719:Glucuronides; D007527:Isoenzymes; D014453:Glucuronosyltransferase